Document Type |
: |
Article In Journal |
Document Title |
: |
Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1-34). |
Document Language |
: |
English |
Abstract |
: |
BACKGROUND: Recombinant human parathyroid hormone (PTH [1-34];
teriparatide) is a new treatment for postmenopausal osteoporosis that can be
systemically administered for the primary purpose of increasing bone
formation. Because several studies have described the enhancement of
fracture-healing and osteointegration in animals after use of PTH, we sought
to critically analyze this skeletal effect. METHODS: Two hundred and
seventy male Sprague-Dawley rats underwent standard, closed femoral
fractures and were divided into three groups that were administered daily
subcutaneous injections of 5 or 30 mug/kg of PTH (1-34) or vehicle (control).
The dosing was administered for up to thirty-five days. Groups were further
divided into three subgroups and were killed on day 21, 35, or 84 after the
fracture. The bones were subjected to mechanical torsion testing,
histomorphometric analysis, or microquantitative computed tomography.
RESULTS: By day 21, calluses from the group treated with 30 mug of PTH
showed significant increases over the controls with respect to torsional
strength, stiffness, bone mineral content, bone mineral density, and cartilage
volume. By day 35, both groups treated with PTH showed significant
increases in bone mineral content and density and total osseous tissue volume,
and they demonstrated significant decreases in void space and cartilage
volume (p < 0.05). Torsional strength was significantly increased at this timepoint
in the group treated with 30 mug of PTH (p < 0.05). While dosing was
discontinued on day 35, analyses performed after eighty- four days in the group
treated with 30 mug of PTH showed sustained increases over the controls with
respect to torsional strength and bone mineral density. No change was noted in
osteoclast density at the time-points measured, suggesting that treatment with
PTH enhanced bone formation but did not induce bone resorption.
CONCLUSIONS: These data show that daily systemic administration of PTH
(1-34) enhances fracture-healing by increasing bone mineral content and
density and strength, and it produces a sustained anabolic effect throughout the
remodeling phase of fracture- healing. |
ISSN |
: |
0 |
Journal Name |
: |
J Bone Joint Surg Am |
Volume |
: |
78 |
Issue Number |
: |
4 |
Publishing Year |
: |
2005 AH
2005 AD |
Article Type |
: |
Article |
Added Date |
: |
Friday, January 4, 2008 |
|
Researchers
ياسر الخياري | Alkhiary, Yaseer | Investigator | Doctorate | YALKHIARY@Kau.edu.sa |
|